TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Risk of scarring after DWL treatment
Endpoint domain: Adverse events/effects
Primary endpoint: biochemically verified abstinence rates at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative forced expiratory volume at 1 s (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Kidney disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CR rate of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum venoconstriction (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Infusion rate to induce 50% of Emax (ED50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of delirium within 5 days of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Overall incidence of complications at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-∞ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (dizziness)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma measures of FSAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of FVII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking urges elicitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate/severe RP-related symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stricture resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of ERCPs to achieve resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Error (MAE) in warfarin dose prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of predictions within 20% of actual warfarin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving > or =50% improvement in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hepatobiliary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in liver function tests (AST, ALT, GGT, ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of failed attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: tolerance of the suppositories
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early suppository expulsion
Endpoint domain: Adverse events/effects
Primary endpoint: Balance testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Righting reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediolateral sway frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resultant / AP sway frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total HEI-2010 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean 24-h systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: allogeneic transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: economic outcomes associated with alcohol dependence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mortality rate at 3-6 months
Endpoint domain: Mortality/survival
Primary endpoint: overground gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plasma levels of ascorbic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in levels of oxidized ascorbic acid (dehydroascorbate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in lung function (FEV1% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: WOMAC function impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of sinus rhythm at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transmitral A wave velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean time for first morphine demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative response rate (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in left ventricular mass indexed to height1.7 (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of Desmopressin in treating nocturnal enuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of side effects of Desmopressin
Endpoint domain: Adverse events/effects
Primary endpoint: successful termination rate
Endpoint domain: Mortality/survival
Primary endpoint: fewer emergency visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: better quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: unpleasant feeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in refractory rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of TNFR55-IgG1
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative hydromorphone requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: St. Georges Respiratory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6‐min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 52-week smoking abstinence
Endpoint domain: Mortality/survival
Primary endpoint: Night-time blood pressure decrease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wheal area reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal temperature stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoietic engraftment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant-related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative narcotic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in reappraisal ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to primary closure of fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in abdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thumb workspace recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: finger workspace recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV/AIDS knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception of the effectiveness of condoms and abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: spirometric parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of spores in tissue sections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevention of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: KABC-II mental processing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CogState Groton maze learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Central Point Thickness (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBA (Effective Bactericidal Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of penile intromission (SEP2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of intercourse (SEP3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasted triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically significant improvement in subjective parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flu-like side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Glycated haemoglobin (HbA1c) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxycodone consumption reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC(0‐)(t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severe impairment battery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily time spent in physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in moderate to vigorous energy expenditure zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge drinking frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of meeting diagnostic criteria for alcohol abuse and dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive urine cocaine assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean urine benzoylecgonine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of voluntary participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Full epithelial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rates at 12 and 60 months
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in viable counts of MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum concentration level (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to 168 h (AUC(0-168))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity (AUC(0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCG-specific CD4 T cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between PVP and CVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bias between PVP and CVP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prediction of CVP using PVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grades 3-4 intraventricular hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confidence in dispensing hormonal contraceptives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak growth hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to recommended healthy practices after childbirth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IVR utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thoracic kyphosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensing latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nephrotoxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean sensory pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean affective pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of endoscopic retrograde cholangiography examinations until ABS resolution
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initial treatment success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic pill consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: levels of endogenously oxidized DNA bases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of H₂O₂‐induced DNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: point prevalence abstinence during the final week of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-peak (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission or relapse event within 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: needle pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of exercise desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean oxygen saturation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minimal oxygen saturation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total time spent with oxygen saturation level <95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CIBIC plus score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mini-Mental State Examination score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in the number and ratio of gram-positive rods to cocci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion of symptomatic lens wearers to asymptomatic lens wearers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in type I muscle fiber area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal knee strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Choice of stent and use/type of CPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CEC density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Compliance with postoperative oral adjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intercostal and forearm muscle oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAQ angina frequency score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SAQ QoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference from predetermined angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-tidal P(CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: constipation risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean improvement in the time needed to perform all TEMPA tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in the time needed to perform unilateral TEMPA tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in the ballistic component of aimed movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to 1 mm ST deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PSS-10 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SWLS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immunogenicity at 1 month post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody persistence at 6 months post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactogenicity (solicited reactions within 7 days)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in overnight‐fasted plasma quercetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in nocturnal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days lost from work or school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: presence of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular ejection fraction (LVEF) response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Undesired side effects
Endpoint domain: Adverse events/effects
Primary endpoint: well-being (SF12, mcs)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain decrease after 2 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum mouth opening improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glucose values during 0-8 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen consumption at anaerobic threshold (VO2AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO2 pea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Workload at peak level (Lpeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in intrabag volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: indices of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bladder electrical perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean AUC for MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum MTX concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for elastomeric pump
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of subjects requiring oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes